Cell & Gene Therapy Catapult

Cell and Gene

Focused on the development of the UK cell therapy industry to increase the nation's health and wealth, it is to build its £55m state-of-the-art Cell Therapy manufacturing centre on the SBC campus.

The Cell & Gene Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 100 employees focusing on cell and gene therapy technologies, we work with our partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. We offer leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise.

We aim to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. Regenerative medicine is one of the UK government’s eight great technologies that support UK science strengths and business capabilities. The Cell Therapy Catapult is part-funded by Innovate UK, formerly the Technology Strategy Board – the UK’s innovation agency.

ATAC apprentice Emilia Reyes Pabon is proudly working in the team developing the ChAdOx1 #COVID19 vaccine at @UniofOxford's Clinical Biomanufacturing Facility. Read more about her experience and significant impact of this work 💉🧬👩‍🔬👉 ow.ly/ZxuM50ATm4i pic.twitter.com/iI3xbyzgMX

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.